Agomelatine

doi:10.2165/00023210-200620120-00003

Paper

Agomelatine

Published 2006 · Michael J. Zupancic, C. Guilleminault

CNS Drugs

Q1 SJR score

127

Citations

3

Influential Citations

Full textSemantic Scholar

Abstract

Agomelatine is a new antidepressant that is a potent agonist of melatonin receptors and an antagonist of the serotonin 5-HT(2C) receptor subtype. It is in late-phase trials for the treatment of major depressive disorder (MDD). Symptoms of depression significantly improved with agomelatine compared with placebo in large placebo-controlled trials, and agomelatine appears to be as efficacious in treating MDD as other antidepressants but with fewer adverse effects. Agomelatine appears to improve sleep quality and ease of falling asleep, as measured subjectively in depressed patients. Polysomnographic studies have shown that agomelatine decreases sleep latency, decreases wake after sleep onset (WASO), and improves sleep stability as measured by changes in the cyclic alternating pattern. Agomelatine is generally well tolerated in patients with MDD; in clinical trials, adverse events were generally mild to moderate in nature, with an overall frequency close to that of placebo. Discontinuation of agomelatine because of adverse effects occurred at a similar rate to placebo.

Literature Review

Highly Cited

Study Snapshot

Agomelatine is a promising new antidepressant that improves sleep quality and eases falling asleep in depressed patients, with fewer adverse effects than other treatments.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Agomelatine

Sign up to use Study Snapshot

References

Remodeling of neuronal networks by stress.

Chronic stress induces structural changes in neuronal networks, potentially reflecting adaptive responses to changing environmental demands.

A Neurotrophic Model for Stress-Related Mood Disorders

Decreased BDNF expression contributes to depression and upregulation of BDNF plays a role in the actions of antidepressant treatment.

Agomelatine, a New Antidepressant, Induces Regional Changes in Hippocampal Neurogenesis

Agomelatine, a new antidepressant, increases neurogenesis in the ventral dentate gyrus and increases survival of newly formed neurons in the entire dentate gyrus, but does not affect mature granule cells.

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

Agomelatine 25 mg is effective and well-tolerated for treating major depressive disorder, with 50 mg being beneficial for some patients without reducing tolerability.

Melatonin in mood disorders

Melatonin plays a role in the pathophysiology of bipolar disorder and seasonal affective disorder, with bright light treatment effectively suppressing melatonin production in these conditions.

Citations

Lack of Acute Agomelatine Effect in a Model of Social Anxiety in Healthy Volunteers: A Double-Blind, Placebo-Controlled Trial.

Acute administration of a low dose of agomelatine failed to modify behavioral and physiological changes caused by a public speaking test in healthy volunteers.

Intranasal thermosensitive hydrogel of agomelatine solid dispersion for better management of depression

Intranasal thermosensitive hydrogel formulations of agomelatine enhance its bioavailability and antidepressant effect by targeting the brain and avoiding hepatic first-pass metabolism.

Formulation optimization, in vitro and in vivo evaluation of agomelatine-loaded nanostructured lipid carriers for augmented antidepressant effects.

AGM-NLCs show promising potential as nanocarriers for effective delivery of antidepressants to the brain, with enhanced therapeutic effectiveness and reduced inflammatory markers.

Assessing the therapeutic potential of agomelatine, ramelteon, and melatonin against SARS-CoV-2

Melatonin, ramelteon, and agomelatine show potential as antiviral agents against SARS-CoV-2, with ramelteon showing the most superior antiviral properties.

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

Therapeutic drug monitoring and cytochrome P450 genotyping are essential tools for individualized antidepressant therapy, enhancing efficacy and tolerability in patients.

Different molecular targets, one purpose – treatment of depression

Depression has a complex pharmacology and requires individual pharmacotherapy, with this review highlighting new promising molecular targets for treatment.

Trait Sensitivity to Negative and Positive Feedback Does Not Interact With the Effects of Acute Antidepressant Treatment on Hedonic Status in Rats

Trait sensitivity to negative and positive feedback does not significantly interact with the effects of acute antidepressant treatment on hedonic status in rats.